Jessica C Hassel

发表

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world Dermatologic Cooperative Oncology Group study

A. Hauschild, D. Schadendorf, K. Kähler, 2023, European Journal of Cancer.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

J. Utikal, A. Hauschild, S. Haferkamp, 2023, The Lancet.

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition

R. Gutzmer, A. Roesch, D. Vordermark, 2023, Cancers.

Improved survival with ipilimumab in patients with metastatic melanoma.

D. Schadendorf, G. Linette, J. Wolchok, 2010, The New England journal of medicine.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

A. Hauschild, P. Ascierto, R. Dummer, 2016, The New England journal of medicine.

Generalized perforating granuloma annulare: a case report

Adriana Rendon, M. Salzmann, Jessica C Hassel, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

A. Schneeweiss, N. Halama, D. Jäger, 2022, Nature Cancer.

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.

A. Hauschild, D. Schadendorf, L. Heinzerling, 2023, European journal of cancer.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

D. Schadendorf, R. Dummer, M. Casey, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

S100 as Serum Tumor Marker in Advanced Uveal Melanoma

A. Enk, M. Salzmann, Jessica C Hassel, 2023 .

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

A. Abernethy, K. Savage, P. Ascierto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?

A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, C. Sachpekidis, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

R. Sullivan, J. Sosman, J. McQuade, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.

M. Weichenthal, J. Utikal, D. Schadendorf, 2023, Frontiers of medicine.

Comparison of molecular abnormalities in vulvar and vaginal melanomas

P. Schirmacher, R. Penzel, C. Gilks, 2014, Modern Pathology.

Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer

R. Schneiderbauer, A. Enk, S. Fröhling, 2017, The British journal of dermatology.

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients

A. Gesierich, S. Goerdt, C. Garbe, 2018, The British journal of dermatology.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

A. Hauschild, H. Lipp, F. Lordick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

J. Utikal, C. Berking, D. Schadendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

J. Utikal, C. Berking, D. Schadendorf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

M. Weichenthal, A. Hauschild, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

K. Savage, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

D. Schadendorf, H. Kurzen, R. Dummer, 2010, British Journal of Cancer.

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

B. Chmielowski, J. Piulats, M. Orloff, 2023, The New England journal of medicine.

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

K. Kähler, F. Meier, D. Göppner, 2023, Melanoma research.